TRDA — Entrada Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1689375 ·
Last close
$4.96
Market Cap
$194.19M
52W High
$16.45
52W Low
$4.11
ADV30
471,289
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 898,000 — -44,963,000 -42,763,000 298,877,000 99,280,000 65,466,000
Mar 2026 875,000 — -42,303,000 -39,717,000 335,518,000 76,444,000 64,664,000
Dec 2025 1,299,000 — -42,208,000 -39,164,000 377,378,000 90,394,000 71,245,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-134,674,000
Investing CF
$160,164,000
Financing CF
$650,000
CapEx
$-1,474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.84
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-355,574,000
Inventory
—
Receivables
$816,000
ST Investments
$123,725,000
EBIT TTM
$-176,525,000
Pretax Income TTM
$-164,959,000
Interest Exp TTM
—
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,686,000
EBITDA
$-170,863,008
Free Cash Flow
$-77,671,624
Enterprise Value
$7,987,339
Total Cash
$223,004,992
Total Debt
$48,544,000
Shares Out
39,150,334
Trailing EPS
$-3.84
Book Value
$8.50
ROE
-54.1%
ROA
-29.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 25,421,000 -157,898,000 -143,750,000 377,378,000 71,245,000 306,133,000 -128,512,000
Dec 2024 210,782,000 47,011,000 65,626,000 526,321,000 97,643,000 428,678,000 -41,557,000
Dec 2023 129,013,000 -3,162,000 -6,685,000 469,192,000 226,832,000 242,360,000 139,803,000
Dec 2022 0 -97,248,000 -94,616,000 252,056,000 39,502,000 212,554,000 -93,786,000

TTM Snapshot

Revenues TTM
$4,686,000
NetIncome TTM
$-165,778,000
OpCashFlow TTM
—
Assets (Latest)
$298,877,000
Forward EPS
$-3.20

Max Pain — expiry 2026-12-18

max pain strike: $5.00 · spot: $5.03 · call oi: 5,102 · put oi: 79
Expected Move to 2026-12-18: ±$2.13 (42.35%) — implied range $2.90 – $7.16 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SIGA SIGA TECHNOLOGIES INC $196.16M $2.73 —
ADCT ADC Therapeutics SA $189.89M $1.35 —
VOGX Vogenx, Inc. $200.25M $13.48 —
DRUG BRIGHT MINDS BIOSCIENCES INC. $201.25M $20.51 —
RNAC Cartesian Therapeutics, Inc. $186.68M $6.12 —

News headlines (Yahoo Finance, 1h cache)

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
2026-11-18 08:00 · Yahoo
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 13:35 · Yahoo
Entrada Therapeutics Reports Third Quarter 2026 Financial Results
2026-11-05 12:00 · Yahoo
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
2026-10-21 11:00 · Yahoo
What's Going On With Entrada Therapeutics Stock Wednesday?
2026-10-14 16:47 · Yahoo
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
2026-10-14 11:00 · Yahoo
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
2026-10-14 11:00 · Yahoo
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
2026-09-10 11:00 · Yahoo
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 20:30 · Yahoo
Entrada’s stock drops as DMD drug’s efficacy falls short
2026-05-08 10:39 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.